1 Boosting the power of rare variant association studies by imputation

2 using large-scale sequencing population

- 3 **Running head:** rare variant imputation and genome-wide association study
- 4
- 5 Jinglan Dai, MS^{1#}; Yixin Zhang, MS^{1#}; Zaiming Li, MS¹; Hongru Li, MS¹; Sha Du,
- 6 PhD^{1,2}; Dongfang You, PhD^{1,3}; Ruyang Zhang, PhD^{1,4}; Yang Zhao, PhD^{1,4}; Zhonghua
- 7 Liu⁵, PhD; David C. Christiani, MD^{6,7}; Feng Chen, PhD^{1,2,3*}; Sipeng Shen, PhD^{1,2,4*}
- 8
- ⁹ ¹Department of Biostatistics, Center for Global Health, School of Public Health,
- 10 Nanjing Medical University, Nanjing 211166, China
- ²Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu
 Collaborative Innovation Center for Cancer Personalized
- 13 Medicine, Nanjing Medical University, 211166, Nanjing, China
- ¹⁴ ³China International Cooperation Center of Environment and Human Health, Nanjing
- 15 Medical University
- ⁴Key Laboratory of Biomedical Big Data of Nanjing Medical University, Nanjing
 211166, China
- ⁵Department of Biostatistics, Columbia University, New York, NY, USA
- ⁶Department of Environmental Health, Harvard T.H. Chan School of Public Health,
- 20 Harvard University, Boston, MA 02115, USA
- ²¹ ⁷Pulmonary and Critical Care Division, Massachusetts General Hospital, Department
- 22 of Medicine, Harvard Medical School, Boston, MA 02114, USA
- [#]These authors contributed equally to this study.
- 24

25 *Send correspondence to:

- 26 Dr. Sipeng Shen, SPH Building Room 406, 101 Longmian Avenue, Nanjing, Jiangsu
- 27 211166, China. Email: <u>sshen@njmu.edu.cn</u>
- 28 Dr. Feng Chen, SPH Building Room 412, 101 Longmian Avenue, Nanjing, Jiangsu
- 29 211166, China. Email: <u>fengchen@njmu.edu.cn</u>
- 30
- 31

32 Abstract

33 Rare variants can explain part of the heritability of complex traits that are ignored by 34 conventional GWASs. The emergence of large-scale population sequencing data 35 provides opportunities to study rare variants. However, few studies systematically 36 evaluate the extent to which imputation using sequencing data can improve the power 37 of rare variant association studies. Using whole genome sequencing (WGS) data (n =38 150,119) as the ground truth, we described the landscape and evaluated the 39 consistency of rare variants in SNP array (n = 488,377) imputed from TOPMed or 40 HRC+UK10K in the UK Biobank, respectively. The TOPMed imputation covered 41 more rare variants, and its imputation quality could reach 0.5 for even extremely rare 42 variants. TOPMed-imputed data was closer to WGS in all MAC intervals for three 43 ethnicities (average Cramer's V>0.75). Furthermore, association tests were performed 44 on 30 quantitative and 15 binary traits. Compared to WGS data, the identified rare 45 variants in TOPMed-imputed data increased 27.71% for quantitative traits, while it 46 could be improved by ~10-fold for binary traits. In gene-based analysis, the signals in 47 TOPMed-imputed data increased 111.45% for quantitative traits, and it identified 15 48 genes in total, while WGS only found 6 genes for binary traits. Finally, we 49 harmonized SNP array and WGS data for lung cancer and epithelial ovarian cancer. 50 More variants and genes could be identified than from WGS data alone, such as 51 BRCA1, BRCA2, and CHRNA5. Our findings highlighted that incorporating rare 52 variants imputed from large-scale sequencing populations could greatly boost the 53 power of GWAS.

54

55 Keywords: rare variant; genotype imputation; whole-genome sequencing; association
56 analysis

57

58 Introduction

59 Conventional genome-wide association studies (GWASs) are well-powered to detect 60 thousands of common variants associated with human traits and diseases [1-3]. 61 However, GWASs underrepresent rare variants due to the limitations of SNP array [4]. 62 Rare variants have larger effects and behave differently from common variants to 63 explain a fraction of human traits or disease heritability [5, 6]. With the emergence of 64 next-generation sequencing (NGS) [e.g., whole genome sequencing (WGS)] based on 65 biobank-level populations, massive rare variants [minor allele frequency (MAF)<0.01] 66 or ultra-rare variants (MAF<0.0001) could be accurately captured [7]. For example, 67 several studies aimed at identifying novel germline variants in cancer or rare diseases 68 have benefited from NGS [8, 9].

69 However, given that the application of deep WGS is limited by cost for large-scale 70 populations [10], SNP array is a cost-effective and major approach for human 71 genomics exploration thus far, such as UCLA ATLAS [11], China Kadoorie Biobank 72 [12], FinnGen [13], and various case control GWASs [14]. Even if there are 73 high-quality population-based sequencing data, the incidence number of complex 74 disease cases is often low and the power for identifying rare variants is insufficient 75 compared to case \Box control studies based on SNP array. For example, the UK Biobank 76 (UKB) has whole-exome sequencing (WES) data with a large sample size (n \approx 77 450,000) [15, 16], but most cancer cases have a sample size of less than 10,000. 78 Nevertheless, unlike sequencing data, SNP array-based genotyping can only represent 79 a fraction of the genetic variation in the genome. Thus, it is a more appropriate 80 method to power association analysis to detect rare variants that were not genotyped 81 to the SNP array by imputing from the external high-quality large-scale sequencing 82 panels [10, 17], such as the UK10K, Haplotype Reference Consortium (HRC) and 83 Trans-Omics for Precision Medicine (TOPMed). In TOPMed, 290 million (~97%) 84 variants had an MAF <1%, which might be strong candidates for association analyses

[18, 19]. However, few studies have focused on evaluating the accuracy of rare
variant imputation based on sequencing data panel and the extent to which it can
enhance the power of rare variant exploration.

Here, we present a comparative study that leverages the WGS data of 150,119 individuals from the UKB as the ground truth to evaluate the coverage and accuracy of rare variant imputation using HRC+UK10K and TOPMed. We investigated the association tests of WGS data and imputed variants with 30 biochemistry biomarkers and 15 complex diseases, respectively. Finally, we harmonized WGS data and diverse SNP array data to reveal the rare variant signals in lung cancer and epithelial ovarian cancer.

95

96

97 **Results**

98 Landscape of rare variant imputation results

99 We analyzed WGS data from 150,119 individuals and genotype imputation data 100 generated from the HRC+UK10K and TOPMed reference panels (n=488,377) from 101 the UKB, respectively (Figure 1). The intersection of variants between WGS and 102 imputed data is shown in Figure 2A. TOPMed imputed a substantially larger number 103 of genetic variants that could detect approximately 26% single nucleotide variants 104 (SNVs) of WGS data, which was higher than the 10.7% detected in HRC+UK10K. 105 The TOPMed-imputed data could detect 22 million singleton and doubleton variants, 106 which was far more than HRC+UK10K-imputed data but was still fewer than 333 107 million variants in WGS data. For ultra-rare variants, the TOPMed-imputed variants 108 could reach 66.6% of WGS and were ~3.4-fold of that in HRC+UK10K. For rare and 109 common variants, the number of imputed variants was close to WGS (Figure 2B and 110 Table S1). For protein-coding variants, TOPMed-imputed data detected 44,440 111 loss-of-function (LoF) variants, 509,759 synonymous variants and 880,589 missense

112 variants, which was at least four-fold greater than that in the HRC+UK10K113 imputation (Figure 2B).

To deeply understand the performance of different imputed data compared to WGS,
all variants were divided into five intervals according to the minor allele count (MAC).
As expected, we observed an increase in the fraction of variants as MAC increased.
When MAC∈(10,20], TOPMed-imputed data had already detected ~65% variants of
WGS data, HRC+UK10K-imputed data could only detect ~20% (Figure 2C and Table
S2).
For the imputed data, post-imputation quality control (QC) is generally performed

based on INFO/RSQ filtering. The number of different INFO/RSQ variants in the imputed data is presented in Figure 2D. TOPMed-imputed data achieved substantially higher coverage of rare variants than HRC+UK10K, and as the MAC increased, the proportion of high-quality TOPMed-imputed variants with higher INFO/RSQ increased. Even for extremely rare variants (MAC \in (0,5)), the average INFO/RSQ of imputed data could also reach 0.5 (Table S3).

127 Evaluation of genotype consistency between WGS and imputed data

128 We used WGS data as the ground truth to conduct correlation analysis on the two 129 imputed datasets to evaluate the consistency of rare variants in three ethnicities 130 (White, Asian and African) (Table S4). TOPMed had a better imputation performance 131 that was closer to WGS than HRC+UK10K in all MAC intervals, and the average 132 Cramer's V imputed by TOPMed was above 0.75 in three ethnicities (Figure 3A and 133 Table S5). Even for MAC \in (0,5), the Cramer's V of TOPMed-imputed data exceeded 134 0.6 in all ethnicities. The difference in Cramer's V of various intervals between 135 TOPMed-imputed data and HRC+UK10K-imputed data reached a maximum in 136 extremely rare variants (MAC \in (0, 5)), which was 0.33 for White, 0.25 for Asian and 137 0.17 for African (Figure 3A and Table S5).

138 We also described the relationship between INFO/RSQ and Cramer's V (Figure 3B). 139 With the increase in INFO/RSQ bins, Cramer's V also increased in all three 140 ethnicities, indicating that the variants with high imputation quality could be closer to 141 the WGS data to some extent. Moreover, for the same INFO/RSQ bin, using different 142 reference panels would obtain different Cramer's V, and the consistency of 143 TOPMed-imputed data was higher than that of HRC+UK10K in each bin. Even when 144 the imputation quality was not particularly good (INFO/RSQ \in (0.3,0.4]), the 145 TOPMed-imputed data had an advantage over that from HRC+UK10K which showed 146 a stable consistency (all Cramer's V>0.5 in three ethnicities) (Table S6). Therefore, 147 the rare variants imputed from TOPMed were applicable for subsequent association 148 analysis.

149 Rare variant association analysis for quantitative biochemistry

150 *biomarkers*

151 We performed association tests between rare variants (MAF<0.01) and 30 152 biochemistry biomarkers in WGS (n=150 k) and imputed data (n=150 k and 480 k) of 153 European descent. In the single-variant tests of 16 traits, compared to WGS data, the 154 two imputed data (n=480 k) could detect more significant rare variants; 155 HRC+UK10K-imputed data could improve 4.7% while the TOPMed-imputed data 156 could improve 27.71% (Figure 4A-4B). However, the number of significant rare 157 variants found in WGS data was more than that of imputed data in 12 traits, which 158 might be due to the extremely large number of sequencing sites in WGS. Meanwhile, 159 we noticed that the imputed data of n=150 k had a weaker ability to detect rare 160 variants than WGS (Figure S2). On average, the number of significant rare variants in 161 the TOPMed-imputed data was 661 and in the HRC+UK10K-imputed data was 450, 162 which were less than 2,479 in WGS data (Table S7).

We also evaluated the gene-based tests results to capture the effects of rare variants.On average, 22 genes were found in the TOPMed-imputed data and 18 genes were

found in the HRC+UK10K-imputed data (n=480 k), while the WGS data identified only 7 genes for all traits (Table S8). The average improvement ratio of the HRC+UK10K-imputed data was 55.81%, and that of the TOPMed-imputed data reached 111.45% (Figure 4B). When comparing the WGS data with the imputed data of n=150 k, the number of significant genes in the TOPMed-imputed data decreased by 27.10%, while that in the HRC+UK10K-imputed data decreased by 33.66% (Figure S2).

172 Based on these association tests of the significant variants, we depicted the 173 relationship between the chi-square statistics of the association analysis in WGS data 174 and two imputed data (n=150 k). The test statistics in different imputed data both 175 presented a strong relationship with that in WGS data, which meant their association 176 test statistics were highly correlated (on average, Pearson's r = 0.97 for 177 TOPMed-imputed data and 0.95 for HRC+UK10K-imputed data) (Figure 4C and 178 Table S9). Therefore, the rare variant-trait associations using imputed genotypes were 179 robust.

180 *Rare variant association analysis for complex diseases*

181 We also conducted single-variant tests and gene-based tests for 15 complex diseases, 182 including ten chronic diseases and five cancers (Table S10). In single-variant tests, the 183 number of significant rare variants in the imputed data (n=480 k) was approximately 184 10-fold that in WGS data, owing to its larger sample sizes with sufficient disease 185 cases (Figure S1 and Table S13). On average, 22 significant rare variants were 186 identified in TOPMed-imputed data, and 24 were identified in HRC+UK10K-imputed 187 data. However, only 2 variants could be found in the WGS data on average (Figure 5 188 and Table S11). We also found that for the imputed data with a sample size of 150 k, 189 its ability to detect rare variants was a slightly weaker than that of WGS (Figure S3). 190 Therefore, it could be expected that using large-scale SNP array-based data imputed 191 from sequencing panels would greatly improve the ability of rare variant findings

192 compared to WGS data.

193 In the gene-based tests, the number of significant genes in the imputed data was 194 higher than that in the WGS data, and the performance of the TOPMed-imputed data 195 was better. HRC+UK10K-imputed data could find 14 significant genes in total, and 196 the TOPMed-imputed data could find 15 genes, while the WGS data only found six 197 genes owing to low cases (Figure 5 and Table S12, S14). In addition, we also noticed 198 that some classical genes identified in the two imputed datasets were roughly 199 consistent but undetected in WGS. For example, IL33 has been certified to be 200 associated with asthma and a rare mutation in *IL33* could decrease the risk of asthma 201 [20, 21]. For prostate cancer, the gene CHEK2 which was found only in 202 TOPMed-imputed data has been confirmed to be a risk gene containing rare variants 203 [22]. Most genes found in the TOPMed-imputed data had supporting association or 204 biological evidence from previous studies (Table S21).

Based on the results above, we concluded that incorporating SNP array imputed from
large-scale sequencing populations could enhance the ability to detect rare
variant-trait associations.

208 *Powering the rare variant hits by harmonizing WGS and SNP array*

209 Furthermore, we leveraged UKB WGS and several SNP array data imputed by the 210 TOPMed reference panel to perform association tests for lung cancer (LC) and 211 epithelial ovarian cancer (EOC) (Figure 6A, 6D). Compared with limited cases in 212 WGS ($n_{LC} = 1,494$; $n_{EOC} = 628$), the SNP array could provide sufficient cases ($n_{LC} =$ 213 23,168; n_{EOC} = 23,822) that were 16-fold and 38-fold for LC and EOC respectively. 214 In single-variant tests, no rare variants could pass the genome-wide significance level 215 in WGS. However, when combined with SNP-array data, we detected 12 SNVs and 216 22 SNVs, mapping to six and four independent genetic regions, respectively (Figure 6B, 6E, Table S17-S18). In gene-based tests, no genes could pass $P < 2.5 \times 10^{-6}$ in WGS. 217

218 In the meta-analysis, we identified BRCA2 and CHRNA5 in lung cancer, while

- 219 BRCA2 and BRCA1 were significant in EOC (Figure 6B, 6E, Table S19-S20). Using
- 220 different *P* value thresholds, the WGS+SNP-array strategy could detect more variants,
- especially under stringent thresholds (e.g., 10^{-7} in single-variant and 10^{-5} in gene-based)
- 222 (Figure 6C, 6F).
- 223
- 224

225 **Discussion**

226 It is a common practice to directly apply sequencing data or imputed genotype data to 227 GWAS. Limited by the cost of NGS technology, biobank-level sequencing data are 228 still in the minority [23], resulting in the difficulty of using rare variant analysis which 229 provides important genomic architectures. Large-scale GWASs tend to use imputed 230 genotype data, but few studies systematically compare the power of imputed data for 231 rare variants. Therefore, evaluating the consistency and association power 232 performance of rare variants imputed from sequencing data can provide better 233 guidance and reference for rare variant exploration in complex traits.

234 In this study, we comprehensively conducted a series of comparative analyses for rare 235 variant imputation using SNP array data from the UKB based on TOPMed or 236 HRC+UK10K against the WGS data of 150,119 individuals as the ground truth. We 237 described the rare variant imputation results, and further carried out the correlation 238 analysis in three ethnicities (White, Asian, and African) to evaluate how close rare 239 variant imputation could be to WGS data. We further investigated association analysis 240 on 30 biochemistry markers and 15 complex diseases to explain the ability of imputed 241 rare variants to improve the association analysis at both single-variant and gene-based 242 levels.

Our summarized description shows that the TOPMed panel could impute more high-quality rare variants than HRC+UK10K. Although the imputed variants were far inferior to WGS in singleton and doubleton variants, the total number of rare variant

imputed by TOPMed also had a certain scale. Even for the extremely rare variants
(MAC<5), the average imputation quality of TOPMed-imputed variants was
acceptable (INFO/RSQ≥0.5). Although not all rare variants can be estimated reliably,
they could provide a crucial supplement in addition to WGS.

250 For the three ethnicities, we observed that rare variants imputed from TOPMed were 251 closer to WGS than those imputed from HRC+UK10K in each MAC interval. In 252 Europeans, the consistency of rare variants with MAC≤20 in HRC+UK10K-imputed 253 data is poor, which is not recommended for subsequent application. In addition, the 254 overall correlation between TOPMed-imputed data and WGS was slightly stronger in 255 Africans than in the other two ethnicities, which may be due to the low sample size of 256 Africans (n<1,000) in WGS, and unbalanced ethnic sample sizes affect the stability of 257 Cramer's V. Nevertheless, the TOPMed-imputed data still had a stable imputation 258 performance that was closer to WGS data, indicating its reliability to be applied in 259 rare variant association studies.

260 In the association analysis of quantitative and binary traits, although the ability of 261 both imputed data to identify significant rare variants was weaker than that of WGS 262 data in the same population (n = 150k), we could still identify a few rare variants or 263 gene sets. When the sample size of the imputed data increased to n = 480 k, the ability 264 to identify significant rare variant could improve, but this improvement was slightly 265 different in distinct types of traits. For quantitative traits, the power of WGS data for 266 finding significant rare variants was basically sufficient, and the two imputed data had 267 limited improvement compared to WGS data. However, for binary traits, the number 268 of disease cases in WGS data was far from sufficient to ensure optimistic power, 269 causing fewer significant rare variants to be found. To improve the power, external 270 data with additional disease cases must be supplemented. Our study indeed showed 271 that larger SNP array data imputed from sequencing data could greatly improve the 272 ability to find significant rare variants.

273 Although the natural population cohorts are large with adequate sample sizes, the 274 disease cases are generally insufficient, which is known as a case \Box control imbalance 275 problem and leads to low statistical power to identify rare variants [24]. Here, we 276 harmonize WGS population and multiple case control design GWASs and 277 successfully identify classical rare variants and gene sets in two cancers, including the 278 well-known BRCA2 [25], BRCA1 [26], and CHRNA5 [27], which could not be 279 detected in UKB WGS. Therefore, integrating SNP-array data through imputation is 280 of great significance for discovering rare variants.

281 There are several strengths in our study. First, we comprehensively described the 282 landscape of the imputed rare variants from different sequencing panels in terms of 283 variant amount, coverage, and imputed quality. Second, we leveraged WGS data as 284 the ground truth to perform correlation analysis by different ethnicities, and analyzed 285 their consistency with imputed rare variants. We demonstrated the feasibility of using 286 imputed rare variants for association analysis. Third, we conducted various 287 association tests on 45 traits of the UKB and harmonized six GWAS case control 288 datasets totally. Through both single-variant and gene-based tests, we quantitatively 289 explained the improvement of SNP array-based data imputed from sequencing data in 290 rare variant association studies.

291 The results we presented here also have some limitations. First, our genotype 292 consistency evaluation was only conducted on the UKB SNP array (~50,000 UK 293 BiLEVE Axiom array and ~450,000 UK Biobank Axiom array) that did not consider 294 other array types, which might influence the results. Second, we currently impute the 295 genotype in TOPMed's imputation online server (97,256 reference samples) due to 296 computing power limitations, but it is convenient and feasible for most genomic 297 studies. Theoretically, the results of imputation in larger populations (e.g., UKB 298 whole WGS population) should be more accurate [28], which needs further studies to 299 confirm. Third, we attempted to integrate the SNP-array data and sequencing data in 300 two exemplary cancers. The effect of integrating other various diseases in large-scale

301 population cohorts ($n \ge 100,000$) needs further evaluation.

In conclusion, incorporating rare variants imputed from large-scale sequencing populations can greatly enhance the power of GWAS research. Our study shows that combining multi-source genomic data with a sufficient number of cases can accurately identify a wider range of rare variants, allowing us to take full advantage of different types of genetic data and to gain a deeper understanding of the causal links between rare genetic variants in human complex traits and diseases.

308

309

310 Methods

311 UK Biobank population and phenotypic data collection

The UK Biobank (UKB) is a population-based prospective cohort of individuals aged 40–69 years, enrolled between 2006 and 2010 [29]. The work described herein was approved by the UK Biobank under applications no. 92675 and 83445. All phenotypic data were accessed in July 2022.

Blood biochemistry data were collected from Category 17518. The UK Biobank embarked on a project to measure a wide range of biochemical markers in biological samples collected at baseline (2006-2010) in all 500,000 participants. All 30 biochemistry biomarkers were included as quantitative traits.

320 Health-related outcomes were ascertained via individual record linkage to national 321 cancer and mortality registries and hospital in-patient encounters. Cancer diagnoses 322 were coded by International Classification of Diseases version 10 (ICD-10) codes 323 from data fields 41270 (Diagnoses - ICD10), 41202 (Diagnoses - main ICD10), and 324 40001 (primary cause of death: ICD10). Individuals with at least one recorded 325 incident diagnosis were defined as cases. We included 15 common chronic diseases or 326 cancers as binary traits, including insulin-dependent diabetes mellitus,

non-insulin-dependent diabetes mellitus, obesity, depressive episode, hypertension,
chronic ischemic heart disease, heart failure, COPD, asthma, cholelithiasis, bladder
carcinoma, breast carcinoma, non-Hodgkin lymphoma, prostate cancer, and
Melanoma.

331 UK Biobank genomics data collection

332 We collected whole-genome sequencing (WGS) of 150,119 people in the UK Biobank 333 (data field 23352) [30], which were sequenced to an average coverage of $32.5\times$ (at 334 least 23.5× per individual) using Illumina NovaSeq sequencing machines at deCODE 335 Genetics (90,667 individuals) and the Wellcome Trust Sanger Institute (59,452 336 individuals). Sequence reads were mapped to the human reference genome GRCh38 337 using BWA. SNPs and short indels were jointly called over all individuals using 338 GraphTyper (v2.7.1) [31], which provided more accurate genotype calls. This 339 constitutes a set of high-quality variants, including 585,040,410 single-nucleotide 340 variants (SNVs) and 58,707,036 indels.

341 We also collected imputed genotype data based on two mainstream reference panels. 342 The first is the Haplotype Reference Consortium (HRC) and UK10K haplotype 343 resource, which increases the number of testable variants over 100-fold to ~96 million 344 variants (data field 22828). The genetic data was imputed using two different 345 reference panels. The HRC panel (64,976 haplotypes) was used wherever possible, 346 but for SNPs not in that reference panel the UK10K + 1000 Genomes panel (12,570) 347 haplotypes) was used [32]. The raw positions are in GRCh37 coordinates and then 348 lifted over to GRCh38.

The second is imputation from genotype using the TOPMed R2 panel (97,256 deeply sequenced genomes), performed by the TOPMed Informatics Research Center [33]. After phasing the UK Biobank genetic data (carried out on 81 chromosomal chunks using Eagle v.2.4), the phased data were converted from GRCh37 to GRCh38 using LiftOver. Imputation was performed using Minimac4 v1.0.2. Imputation was

354 performed in 1 Mb chunks and merged back together by chromosome.

355 Quality control of imputed SNP array data

356 If an imputed variant on N samples has an imputation quality metric scored at α , it 357 implies that the statistical power of association tests is approximately equivalent to αN 358 perfectly observed genotype data [34]. To perform GWAS on the UK Biobank data 359 with ~480,000 samples, it is typical to use variants with imputation quality higher 360 than 0.3, equivalent to \sim 150,000 perfectly observed samples (WGS sample size). Thus, 361 markers with poor imputation quality were not retained in the subsequent analysis 362 (excluding the Minimac4 imputation quality metric RSQ < 0.3 or IMPUTE 363 imputation quality metric INFO < 0.3).

364 *Genotype consistency evaluation*

In two imputed datasets (TOPMed and HRC+UK10K) and WGS data, we divided the population into three ethnicities --- White, Asian, African based on ethnic data field 21000. To evaluate the consistency between the imputed genotype and WGS data, we matched the imputed data (n=480k) with the WGS data (n=150k) according to the individual ID of each ethnicity.

Then, we used PLINK2.0 to calculate the number of minor allele count (MAC) and minor allele frequency (MAF) of genetic variants in each ethnicity. Meanwhile, based on MAC and MAF, genetic variants were classified into five categories, namely (0,5], (5,10], (10,20], (20,50], >50 and MAF<0.01 (the interval was abbreviated as > 50 in the subsequent analysis). We chose Cramer's V as the metric to evaluate the consistency of imputed variants and sequencing variants:

Cramer's V =
$$\sqrt{\chi^2/nm}$$

376 where χ^2 represents the chi-square value of the current contingency table, n represents 377 the sample size, and m represents the smaller value of the two degrees of freedom (r-1)

378 or (c-1) of the two variables.

379 Single-variant and gene-based association tests

Single-variant and gene-based association analyses were performed using REGENIE v3.2.6 [35]. It is a machine-learning based method to fit a whole-genome regression model for quantitative and binary phenotypes. Quantitative traits were rank-based inverse normal transformed. Saddlepoint approximation (SPA) was used to handle extreme case control imbalance of binary traits. All association tests were performed in the population of European descent (ethnicity = "White") only.

The single-variant association tests included rare variants with MAF < 0.01. The variants were functionally annotated using Variant Effect Predictor (VEP) software [36]. The genome-wide significant threshold of single-variant tests was set to $P < 5 \times$ 10^{-8} .

For gene-based analysis, we included rare and ultra-rare variants with MAF < 0.01. Three genetic models were considered: loss of function (LoF), LoF+missense and LoF+missense+synonymous. Of all the combinations, we reported the association results with the lowest *P* value to collectively capture a wide range of genetic architectures [5]. The genome-wide significance threshold of gene-based tests was set to $P < 2.5 \times 10^{-6}$.

In the association analyses of quantitative traits, we adjusted the covariates including age, sex, and the top ten principal components (PCs). In the association analyses of binary traits, we adjusted the covariates including age, sex (excluding sex-specific diseases), body mass index (BMI), smoking status (binary), drinking status (binary), and the top ten principal components (PCs).

401 SNP array data collection for lung cancer and ovarian cancer

We also collected large-scale SNP array data of lung cancer and epithelial ovariancancer to harmonize them with UKB WGS to improve the power.

404 For lung cancer, we investigated the association of imputed genetic variants with lung 405 cancer in three additional cohorts from the Prostate, Lung, Colorectal, and Ovarian 406 (PLCO) cancer screening trial [37], the International Lung Cancer OncoArray 407 Consortium (ILCCO-OncoArray) [38], and the Transdisciplinary Research in Cancer 408 of the Lung (TRICL) research team [39] (Table S15). 409 For ovarian cancer, we collected data in three additional cohorts from The Follow-up 410 of Ovarian Cancer Genetic Association and Interaction Studies (FOCI)-OncoArray 411 [40], FOCI-Exome Chip [41], and Consortium of Investigators of Modifiers of 412 BRCA1/2 (CIMBA) [42] (Table S16). 413 Samples excluded were those who lacked disease status, were second-degree relatives

or closer having identity by descent (IBD) > 0.2 or had low-quality DNA (call rate < 95%), or sex inconsistency, or were non-European. SNPs were removed if they met of the following criteria: (1) sex chromosome, (2) MAF < 0.05, (3) call rate < 95%, and (4) Hardy-Weinberg equilibrium (HWE) test $P < 1.00 \times 10^{-7}$ in controls or $P < 1.00 \times 10^{-12}$ in cases.

419 All genotype data were imputed on the TOPMed online imputation server. Poorly 420 imputed SNVs with imputation quality score $R^2 < 0.3$ and SNVs on sex chromosomes 421 were excluded from the analyses. The effect sizes and 95% confidence interval (CI) of 422 genes were estimated by burden tests and then summarized by fix-effects 423 meta-analysis.

424

425

426

427 **Declarations**

428 **Consent for publication**

429 All authors have reviewed and approved this manuscript.

430 Data availability

431 UK Biobank data is available from: <u>https://www.ukbiobank.ac.uk/</u>.

432	ILCCO-Oncoarray data is available from:			
433 434	$\frac{p_1}{p_2}$			
435 436 437	TRICLdataisavailablefrom:https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001681.v1.p1			
438 439 440	PLCOdataisavailablefrom:https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi-study_id=phs001286.v2.p2.			
441 442 443	FOCI-Exome Chip data is available from: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001131.v1. p1			
444 445 446 447	FOCI-OncoArrayChip:dataisavailablefrom:https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001882.v1.p1&phv=435464&phd=&pha=&pht=10492&phvf=&phdf=&phaf=&phtf=&dssp=1&consent=&temp=1			
448 449 450	CIMBA: data is available from: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001321.v1. p1			
451	Online resources			
452	TOPMED imputation server: https://imputation.biodatacatalyst.nhlbi.nih.gov/.			
453	gnomAD: http://gnomad.broadinstitute.org/.			
454	dnSNP: https://www.ncbi.nlm.nih.gov/snp/.			
455	Code availability			
456	The codes that support our findings are available from the corresponding author by a			
457	request.			
458	Conflicts of interest statements/Financial Disclosure statement			
459	The authors report no conflicts of interest.			
460	Funding			
461	National Natural Science Foundation of China (82373685 and 82373685 to S.S.,			
462	82220108002 to F.C., 82103946 and 82173620 to Y.Z.), Natural Science Foundation			
463	of the Jiangsu Higher Education Institutions of China (21KJB330004 to S.S.), and US			
464	NIH (NCI) grant #U01CA209414 to DCC.			

465 Author contributions

- 466 SS and FC contributed to the study design. SS and JD contributed to data collection.
- 467 JD performed statistical analyses and interpretation. JD and SS drafted the manuscript.
- 468 HL, SD, DY, YZ, RZ, ZL, and DC revised the final manuscript. All authors approved
- the final version of the manuscript.

470 Acknowledgement

- 471 We want to acknowledge the participants and investigators of UK Biobank, TOPMed,
- 472 PLCO, ILCCO-OncoArray, TRICL, FOCI, and CIMBA.

473

474

475 **Reference**

476	1.	Chiou J, Geusz RJ, Okino ML, Han JY, Miller M, Melton R, Beebe E, Benaglio P, Huang S,
477		Korgaonkar K et al: Interpreting type 1 diabetes risk with genetics and single-cell
478		epigenomics. Nature 2021, 594(7863):398-402.
479	2.	Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M,
480		Delplanque J, Lobbens S, Rocheleau G, Durand E et al: A variant near MTNR1B is
481		associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat
482		<i>Genet</i> 2009, 41 (1):89-94.
483	3.	Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, Bugliani M, Saxena R,
484		Fex M, Pulizzi N et al: Common variant in MTNR1B associated with increased risk of
485		type 2 diabetes and impaired early insulin secretion. Nat Genet 2009, 41(1):82-88.
486	4.	Kaisinger LR, Kentistou KA, Stankovic S, Gardner EJ, Day FR, Zhao Y, Mörseburg A, Carnie
487		CJ, Zagnoli-Vieira G, Puddu F et al: Large-scale exome sequence analysis identifies sex-
488		and age-specific determinants of obesity. Cell genomics 2023, 3(8):100362.
489	5.	Wang Q, Dhindsa RS, Carss K, Harper AR, Nag A, Tachmazidou I, Vitsios D, Deevi SVV,
490		Mackay A, Muthas D et al: Rare variant contribution to human disease in 281,104 UK
491		Biobank exomes. Nature 2021, 597(7877):527-532.
492	6.	Karczewski KJ, Solomonson M, Chao KR, Goodrich JK, Tiao G, Lu W, Riley-Gillis BM, Tsai
493		EA, Kim HI, Zheng X et al: Systematic single-variant and gene-based association testing
494		of thousands of phenotypes in 394,841 UK Biobank exomes. Cell Genom 2022,
495		2 (9):100168.
496	7.	Sazonovs A, Barrett JC: Rare-Variant Studies to Complement Genome-Wide Association
497		Studies. Annu Rev Genomics Hum Genet 2018, 19:97-112.
498	8.	Shen S, Li Z, Jiang Y, Duan W, Li H, Du S, Esteller M, Shen H, Hu Z, Zhao Y et al: A
499		Large-Scale Exome-Wide Association Study Identifies Novel Germline Mutations in
500		Lung Cancer. Am J Respir Crit Care Med 2023, 208(3):280-289.
501	9.	Greene D, Pirri D, Frudd K, Sackey E, Al-Owain M, Giese APJ, Ramzan K, Riaz S,
502		Yamanaka I, Boeckx N et al: Genetic association analysis of 77,539 genomes reveals rare
503		disease etiologies. Nature Medicine 2023, 29(3):679-688.
504	10.	Tam V, Patel N, Turcotte M, Bosse Y, Pare G, Meyre D: Benefits and limitations of
505		genome-wide association studies. Nat Rev Genet 2019, 20(8):467-484.
506	11.	Johnson R, Ding Y, Bhattacharya A, Knyazev S, Chiu A, Lajonchere C, Geschwind DH,
507		Pasaniuc B: The UCLA ATLAS Community Health Initiative: Promoting precision
508		health research in a diverse biobank. Cell genomics 2023, 3(1):100243.
509	12.	Walters RG, Millwood IY, Lin K, Schmidt Valle D, McDonnell P, Hacker A, Avery D, Edris A,
510		Fry H, Cai N et al: Genotyping and population characteristics of the China Kadoorie
511		Biobank. Cell genomics 2023, 3(8):100361.
512	13.	Sun BB, Kurki MI, Foley CN, Mechakra A, Chen CY, Marshall E, Wilk JB, Chahine M,
513		Chevalier P, Christé G et al: Genetic associations of protein-coding variants in human
514		disease. Nature 2022, 603(7899):95-102.
515	14.	Abdellaoui A, Yengo L, Verweij KJH, Visscher PM: 15 years of GWAS discovery: Realizing

516		the promise. Am J Hum Genet, 110 (2):179-194.
517	15.	Backman JD, Li AH, Marcketta A, Sun D, Mbatchou J, Kessler MD, Benner C, Liu D, Locke
518		AE, Balasubramanian S et al: Exome sequencing and analysis of 454,787 UK Biobank
519		participants. Nature 2021, 599(7886):628-634.
520	16.	Sun BB, Kurki MI, Foley CN, Mechakra A, Chen CY, Marshall E, Wilk JB, Biogen Biobank T,
521		Chahine M, Chevalier P et al: Genetic associations of protein-coding variants in human
522		disease. Nature 2022, 603(7899):95-102.
523	17.	Barton AR, Sherman MA, Mukamel RE, Loh PR: Whole-exome imputation within UK
524		Biobank powers rare coding variant association and fine-mapping analyses. Nat Genet
525		2021, 53 (8):1260-1269.
526	18.	McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, Kang HM,
527		Fuchsberger C, Danecek P, Sharp K et al: A reference panel of 64,976 haplotypes for
528		genotype imputation. Nat Genet 2016, 48 (10):1279-1283.
529	19.	Wuttke M, Konig E, Katsara MA, Kirsten H, Farahani SK, Teumer A, Li Y, Lang M, Gocmen
530		B, Pattaro C et al: Imputation-powered whole-exome analysis identifies genes associated
531		with kidney function and disease in the UK Biobank. Nat Commun 2023, 14(1):1287.
532	20.	Grotenboer NS, Ketelaar ME, Koppelman GH, Nawijn MC: Decoding asthma: translating
533		genetic variation in IL33 and IL1RL1 into disease pathophysiology. J Allergy Clin
534		Immunol 2013, 131 (3):856-865.
535	21.	Smith D, Helgason H, Sulem P, Bjornsdottir US, Lim AC, Sveinbjornsson G, Hasegawa H,
536		Brown M, Ketchem RR, Gavala M et al: A rare IL33 loss-of-function mutation reduces
537		blood eosinophil counts and protects from asthma. PLoS Genet 2017, 13(3):e1006659.
538	22.	Southey MC, Goldgar DE, Winqvist R, Pylkas K, Couch F, Tischkowitz M, Foulkes WD,
539		Dennis J, Michailidou K, van Rensburg EJ et al: PALB2, CHEK2 and ATM rare variants
540		and cancer risk: data from COGS. J Med Genet 2016, 53(12):800-811.
541	23.	Zhou W, Kanai M, Wu K-HH, Rasheed H, Tsuo K, Hirbo JB, Wang Y, Bhattacharya A, Zhao
542		H, Namba S et al: Global Biobank Meta-analysis Initiative: Powering genetic discovery ac
543		ross human disease. Cell genomics, 2(10):100192.
544	24.	Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, LeFaive J, VandeHaar
545		P, Gagliano SA, Gifford A et al: Efficiently controlling for case-control imbalance and
546		sample relatedn ess in large-scale genetic association studies. Nature genetics,
547		50 (9):1335-1341.
548	25.	Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M,
549		Wei Y, Han Y et al: Rare variants of large effect in BRCA2 and CHEK2 affect risk of
550		lung c ancer. Nature genetics, 46(7):736-741.
551	26.	Hyman DM, Spriggs DR: Unwrapping the implications of BRCA1 and BRCA2 mutations
552		in ovarian ca ncer. JAMA, 307 (4):408-410.
553	27.	Olfson E, Saccone NL, Johnson EO, Chen LS, Culverhouse R, Doheny K, Foltz SM, Fox L,
554		Gogarten SM, Hartz S et al: Rare, low frequency and common coding variants in
555		CHRNA5 and their con tribution to nicotine dependence in European and African
556		Americans. Mol Psychiatry, 21(5):601-607.
557	28.	Hofmeister RJ, Ribeiro DM, Rubinacci S, Delaneau O: Accurate rare variant phasing of

558		whole-genome and whole-exome sequenci ng data in the UK Biobank. Nature genetics,
559		55 (7):1243-1249.
560	29.	Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, Wong E,
561		Liu D, Wade Davis J, Haefliger C et al: Advancing human genetics research and drug
562		discovery through exome seq uencing of the UK Biobank. <i>Nature genetics</i> , 53 (7):942-948.
563	30.	Halldorsson BV, Eggertsson HP, Moore KHS, Hauswedell H, Eiriksson O, Ulfarsson MO,
564		Palsson G, Hardarson MT, Oddsson A, Jensson BO et al: The sequences of 150,119 genomes
565		in the UK Biobank. Nature 2022, 607(7920):732-740.
566	31.	Eggertsson HP, Jonsson H, Kristmundsdottir S, Hjartarson E, Kehr B, Masson G, Zink F,
567		Hjorleifsson KE, Jonasdottir A, Jonasdottir A et al: Graphtyper enables population-scale
568		genotyping using pangenome graphs. Nat Genet 2017, 49(11):1654-1660.
569	32.	Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
570		Delaneau O, O'Connell J et al: Genome-wide genetic data on ~500,000 UK Biobank
571		participants. bioRxiv 2017:166298.
572	33.	Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, Taliun SAG, Corvelo A,
573		Gogarten SM, Kang HM et al: Sequencing of 53,831 diverse genomes from the NHLBI
574		TOPMed Program. Nature 2021, 590(7845):290-299.
575	34.	Marchini J, Howie B: Genotype imputation for genome-wide association studies. Nat Rev
576		Genet 2010, 11 (7):499-511.
577	35.	Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, Benner C,
578		O'Dushlaine C, Barber M, Boutkov B et al: Computationally efficient whole-genome
579		regression for quantitative and binary traits. Nat Genet 2021, 53(7):1097-1103.
580	36.	McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F:
581		The Ensembl Variant Effect Predictor. Genome biology 2016, 17(1):122.
582	37.	Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, Chaturvedi
583		AK, Silvestri GA, Riley TL, Commins J et al: Selection criteria for lung-cancer screening.
584		N Engl J Med 2013, 368 (8):728-736.
585	38.	McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE,
586		Johansson M, Xiao X, Li Y et al: Large-scale association analysis identifies new lung
587		cancer susceptibility loci and heterogeneity in genetic susceptibility across histological
588		subtypes. Nat Genet 2017, 49(7):1126-1132.
589	39.	Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M,
590		Wei Y, Han Y et al: Rare variants of large effect in BRCA2 and CHEK2 affect risk of
591		lung cancer. Nat Genet 2014, 46(7):736-741.
592	40.	Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie
593		A, Riggan MJ, Chornokur G et al: Identification of 12 new susceptibility loci for different
594		histotypes of epithelial ovarian cancer. Nat Genet 2017, 49(5):680-691.
595	41.	Permuth JB, Pirie A, Ann Chen Y, Lin HY, Reid BM, Chen Z, Monteiro A, Dennis J,
596		Mendoza-Fandino G, Group AS et al: Exome genotyping arrays to identify rare and low
597		frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 2016,
598		25 (16):3600-3612.
599	42.	Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, Cimba: An

- 600 international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2
- 601 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2
- 602 (CIMBA). Breast Cancer Res 2007, 9(2):104.
- 603
- 604

605 Figure legends

606 Figure 1. Study workflow

The schematic of the analytical pipeline summarizes the main steps for conducting a comparative study using WGS as the ground truth. We first compared the rare variant imputation for two imputed data (TOPMed-imputed and HRC+UK10K imputed) and WGS data. Then genotype consistency evaluation was investigated on three ethnicities. The rare variant association analysis of 45 traits was carried out after above evaluation in different data. Finally, we harmonized the WGS and SNP-array

613 data for the two cancers.

614 Figure 2. Landscape of rare variant imputation results

615 (A) Venn diagram showing the intersection of variants between TOPMed-imputed

- 616 data, HRC+UK10K-imputed data and WGS data.
- 617 (B) Bar chart showing the number of five distinct variant types for different data (left).
- 618 **Variant type description 1
- 619 Singleton: The minor allele occurs only once in the entire sample
- 620 Doubleton: The minor allele occurs twice in the entire sample
- 621 Ultra-rare variant: MAF<0.0001 except singleton and doubleton
- 622 Rare variant: MAF in 0.0001-0.01
- 623 Common variant: MAF>0.01
- Bar chart showing the number of three distinct variant annotations for differentdata (right).
- 626 (C) Line chart of variant coverage proportions in different imputed data. The x-axis
 627 represents the MAC intervals, and the y-axis represents the proportion of variants
 628 that imputed data could detect related to WGS data.

629 (D) The number of variants imputed by different panels and their distribution across

630 INFO/RSQ bins.

631 Figure 3. Consistency evaluation of the imputed datasets in different ethnicities

- 632 (A)Correlation of three ethnicities between imputed data and WGS data in different
- 633 MAC intervals.
- 634 (B)Box plot of the relationship between the INFO/RSQ of imputed data and the635 Cramer's V.

636 Figure 4. Rare variant association analysis results for biochemistry biomarkers

- 637 (A)The number of additional significant rare variants (MAF<0.01) found in the
- 638 imputed data compared to the WGS data for 30 quantitative traits.
- 639 (B) The average improvement ratio compared to WGS data for single-variant tests and640 gene-based tests.
- 641 (C) Pairwise Pearson correlations between chi-square statistics produced by 642 association tests using imputed data (n=150 k) and WGS data respectively.

643 Figure 5. Rare variant association analysis results for complex diseases

644 Multiple-trait Manhattan plot of single-variant tests and gene-based tests for 15 645 diseases in different data. The x-axis labels each disease, and the y-axis shows $-\log_{10}P$. 646 The red dotted line represents the significance filtering threshold of the *P* value (*P* < 647 5×10^{-8} for single-variant tests, $P < 2.5 \times 10^{-6}$ for gene-based tests), and the gray dotted 648 line represents the suggestive filtering threshold of the *P* value ($P < 5 \times 10^{-6}$ for 649 single-variant tests)

Figure 6. Harmonizing WGS and SNP array to perform association tests for lung cancer (left panel) and epithelial ovarian cancer (right panel)

(A-C) Results of lung cancer. (D-F) Results of epithelial ovarian cancer. (A, D) Circos
plots of the single-variant and gene-based association results using UKB WGS data or
WGS+SNP array data. (B, E) Rare variants and genes identified in each dataset. The

- blocks are marked if the P values reach nominal significance (P < 0.05). (C, F)
- 656 Comparison of the identified signals in the single-variant and gene-based association
- 657 tests under different *P* value thresholds.
- 658
- 659



В

HRC+UK10K TOPMed WGS



423.0M 92.2M 9.8M 51.9M 41.8M 12.1M 3.7M TOPMed HRC+UK10K

•

TOPMed

WGS

D

0.3-0.4 0.4- 0.6 0.6-0.8 0.8-1 INFO/RSQ



MAC intervals

•

HRC+UK10K



С

Α

Α



INFO/RSQ intervals

HRC+UK10K



Single-variant tests

Gene-based tests





P threshold